Why Do We Not Assess Sympathetic Nervous System Activity in Heart Failure Management: Might GRK2 Serve as a New...

Area of Science:

• Cardiology
• Neurocardiology
• Biomarker Discovery

Background:

• Heart failure (HF) is a complex cardiovascular disease characterized by impaired pump function and increased cardiac workload.
• Hyperactivity of the cardiac adrenergic nervous system (ANS) is a key feature of HF, negatively impacting prognosis and increasing mortality.
• Current methods for assessing cardiac ANS function in HF have limitations, hindering clinical application and biomarker implementation.

Purpose of the Study:

• To review current techniques for evaluating cardiac ANS in HF.
• To discuss the role of biomarkers, such as Lymphocyte G-protein-coupled Receptor Kinase 2 (GRK2), in assessing cardiac ANS.
• To explore future perspectives in cardiac ANS evaluation for HF management.

Main Methods:

• Literature review of existing techniques for cardiac ANS assessment in HF.
• Analysis of biomarkers reflecting cardiac ANS activity, focusing on GRK2.
• Discussion of clinical implementation challenges and future research directions.

Main Results:

• Existing methods for cardiac ANS assessment in HF are limited in clinical practice.
• Lymphocyte GRK2 levels correlate with myocardial β-adrenergic receptor function in HF.
• GRK2 shows potential as an independent prognostic biomarker for ANS overdrive in HF.

Conclusions:

• Effective assessment of cardiac ANS in HF remains challenging.
• Lymphocyte GRK2 represents a promising biomarker for evaluating cardiac ANS function and prognosis in HF.
• Further research is needed to integrate novel assessment techniques and biomarkers into routine HF clinical practice.